<DOC>
	<DOCNO>NCT01991301</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy Carfilzumib , novel biological agent use treatment multiple myeloma prevent graft-versus-host disease , stem cell transplantation unrelated donor .</brief_summary>
	<brief_title>Carfilzomib Prevention Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>1 . Patients MDS/AML 2 . 18 year old willing able comply protocol requirement . 3 . LVEF â‰¥ 40 % . 2D transthoracic echocardiogram ( ECHO ) prefer method evaluation . Multigated Acquisition Scan ( MUGA ) acceptable ECHO available . 4 . Patients undergo 810/10 HLA match unrelated unmanipulated PBSC transplantation 5 . Patients condition reduced intensity reduce toxicity conditioning i.e . Fludarabine combine Treosulfan 24 day I.V Busulfan . 6 . Patients must sign write informed consent . 7 . Adequate birth control fertile patient . 1 . Patients undergo type transplantation type basic disease AML MDS . 2 . Patients respiratory failure ( DLCO &lt; 30 % ) . 3 . Active congestive heart failure ( New York Heart Association [ NYHA ] Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention . 4 . Patients &gt; grade II liver renal toxicity . 5 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate 6 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit 7 . Creatinine &gt; 2.0 mg/dl 8 . ECOGPerformance status &gt; 2 9 . Uncontrolled infection 10 . Pregnancy lactation 11 . CNS disease involvement 12 . Pleural effusion ascites &gt; 1 liter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>graft-versus-host disease</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>match unrelated donor</keyword>
	<keyword>proteosmoe inhibitor</keyword>
	<keyword>carfilzumib</keyword>
</DOC>